{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:18:49Z","timestamp":1794867529776,"version":"4.9.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hematological malignancies are a heterogeneous group of diseases caused by disruptions in normal hematopoietic function. This study aimed to evaluate the global burden of hematological malignancies, including Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), and leukemia, with a focus on comparing China and the United States (US).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data from the GLOBOCAN 2022 and Global Burden of Disease (GBD) 2021 were used to estimate the incidence and mortality of hematological malignancies. This study analyzed the age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and estimated annual percentage change (EAPC) to compare trends over time, and risk factors were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In 2022, there were 1,311,104 new cases and 700,205 deaths from hematological malignancies worldwide. Among them, there were 197,438 new cases and 110,367 deaths in China, whereas in the US, there were 181,894 new cases and 58,283 deaths. NHL was the most common type of hematological malignancy, followed by leukemia, MM, and HL globally. Males had higher incidence and mortality rates than females. Compared with China, the US had higher ASIR (30.65\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 9.51 per 100,000) and ASMR (7.33\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 4.73 per 100,000) in 2022. Additionally, the ASIR and ASMR were higher in very high human development index (HDI) countries than in low HDI countries. The incidence of NHL and MM has increased over time, whereas the incidence of HL and leukemia has decreased worldwide. The ASMRs for all types of hematological malignancies, except for MM, have been declining. Furthermore, we identified risk factors contributing to hematological malignancy disability-adjusted life years (DALYs) and deaths, including smoking, high body mass index, and occupational exposure to benzene or formaldehyde. The predicted number of new cases of and deaths from hematological malignancies gradually increased from 2022 to 2050.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study highlights the serious burden of hematological malignancies worldwide, in China, and in the US, emphasizing the urgency for effective prevention and treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003969","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T04:00:15Z","timestamp":1770868815000},"page":"1042-1053","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Disease burden of hematological malignancies worldwide, in China and in the United States based on the GLOBOCAN 2022 and Global Burden of Disease 2021 data"],"prefix":"10.1097","volume":"139","author":[{"given":"Minghao","family":"Lin","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"},{"name":"Peking\u2013Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"R1-20260405","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1101\/gad.284109.116","article-title":"Epigenetics of hematopoiesis and hematological malignancies","volume":"30","author":"Hu","year":"2016","journal-title":"Genes Dev"},{"key":"R2-20260405","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2018.07.003","article-title":"Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care","volume":"33","author":"Damlaj","year":"2019","journal-title":"Blood Rev"},{"key":"R3-20260405","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"R4-20260405","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","article-title":"Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncol"},{"key":"R5-20260405","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J"},{"key":"R6-20260405","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(12)70211-5","article-title":"Global cancer transitions according to the Human Development Index (2008\u20132030): A population-based study","volume":"13","author":"Bray","year":"2012","journal-title":"Lancet Oncol"},{"key":"R7-20260405","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"R8-20260405","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40880-019-0368-6","article-title":"Current cancer situation in China: Good or bad news from the 2018 Global Cancer Statistics?","volume":"39","author":"Feng","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"R9-20260405","doi-asserted-by":"crossref","first-page":"129","DOI":"10.21147\/j.issn.1000-9604.2020.02.01","article-title":"Cancer burden and trends in China: A review and comparison with Japan and South Korea","volume":"32","author":"Sun","year":"2020","journal-title":"Chin J Cancer Res"},{"key":"R10-20260405","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"R11-20260405","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: Profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J"},{"key":"R12-20260405","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R14-20260405","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: A systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"R15-20260405","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"R16-20260405","first-page":"31","article-title":"Partitioning linear trends in age-adjusted rates","volume":"11","author":"Hankey","year":"2000","journal-title":"Cancer Causes Control"},{"key":"R17-20260405","first-page":"46","article-title":"Epidemiological trends of subarachnoid hemorrhage at global, regional, and national level: A trend analysis study from 1990 to 2021","volume":"11","author":"Lv","year":"2024","journal-title":"Mil Med Res"},{"key":"R18-20260405","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/CM9.0000000000001980","article-title":"Comparison of time trends in the incidence of primary liver cancer between China and the United States: An age-period-cohort analysis of the Global Burden of Disease 2019","volume":"135","author":"Zou","year":"2022","journal-title":"Chin Med J"},{"key":"R19-20260405","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/tc.2010.037929","article-title":"Contribution of smoking-related and alcohol-related deaths to the gender gap in mortality: Evidence from 30 European countries","volume":"20","author":"McCartney","year":"2011","journal-title":"Tob Control"},{"key":"R20-20260405","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/cncr.34390","article-title":"Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors","volume":"128","author":"Jackson","year":"2022","journal-title":"Cancer"},{"key":"R21-20260405","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrc3497","article-title":"How ageing processes influence cancer","volume":"13","author":"de Magalh\u00e3es","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"R22-20260405","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41591-023-02655-3","article-title":"The landscape of cancer research and cancer care in China","volume":"29","author":"Lu","year":"2023","journal-title":"Nat Med"},{"key":"R23-20260405","first-page":"31","article-title":"HIV\/AIDS associated lymphoma: Review","volume":"12","author":"Berhan","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"R24-20260405","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1196\/annals.1425.011","article-title":"Poverty and access to health care in developing countries","volume":"1136","author":"Peters","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"R25-20260405","doi-asserted-by":"crossref","DOI":"10.2196\/24813","article-title":"Adoption of electronic health records (EHRs) in China during the past 10 years: Consecutive survey data analysis and comparison of Sino-American challenges and experiences","volume":"23","author":"Liang","year":"2021","journal-title":"J Med Internet Res"},{"key":"R26-20260405","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple Myeloma: A report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"R27-20260405","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cll.2022.04.005","article-title":"Molecular diagnostic testing for hematopoietic neoplasms: Linking pathogenic drivers to personalized diagnosis","volume":"42","author":"Hergott","year":"2022","journal-title":"Clin Lab Med"},{"key":"R28-20260405","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"key":"R29-20260405","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R31-20260405","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"R32-20260405","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12992-021-00731-2","article-title":"Global infectious disease research collaborations in crises: Building capacity and inclusivity through cooperation","volume":"17","author":"Fanning","year":"2021","journal-title":"Global Health"},{"key":"R33-20260405","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.critrevonc.2016.01.003","article-title":"Do the smoking intensity and duration, the years since quitting, the methodological quality and the year of publication of the studies affect the results of the meta-analysis on cigarette smoking and Acute Myeloid Leukemia (AML) in adults?","volume":"99","author":"Colamesta","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"R34-20260405","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.humpath.2023.03.005","article-title":"Smoking status in acute myeloid leukemia is associated with worse overall survival and independent of prior nonhematopoietic malignancies, cytogenetic abnormalities, and WHO category","volume":"135","author":"Kumar","year":"2023","journal-title":"Hum Pathol"},{"key":"R35-20260405","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2021.108365","article-title":"Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer","volume":"787","author":"Caliri","year":"2021","journal-title":"Mutat Res Rev Mutat Res"},{"key":"R36-20260405","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/S0140-6736(21)01169-7","article-title":"Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: A systematic analysis from the Global Burden of Disease Study 2019","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"R37-20260405","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ijc.32109","article-title":"Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies","volume":"145","author":"Psaltopoulou","year":"2019","journal-title":"Int J Cancer"},{"key":"R38-20260405","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/oby.23942","article-title":"Associations between BMI in youth and site-specific cancer in men-A cohort study with register linkage","volume":"32","author":"Onerup","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"R39-20260405","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.toxlet.2024.08.010","article-title":"Benzene exposure and pediatric leukemia: From molecular clues to epidemiological insights","volume":"400","author":"Reynoso-Nover\u00f3n","year":"2024","journal-title":"Toxicol Lett"},{"key":"R40-20260405","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00204-016-1760-5","article-title":"Formaldehyde induces toxicity in mouse bone marrow and hematopoietic stem\/progenitor cells and enhances benzene-induced adverse effects","volume":"91","author":"Wei","year":"2017","journal-title":"Arch Toxicol"},{"key":"R41-20260405","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(19)30160-4","article-title":"Healthy China 2030: Moving from blueprint to action with a new focus on public health","volume":"4","author":"Chen","year":"2019","journal-title":"Lancet Public Health"},{"key":"R42-20260405","article-title":"Availability and affordability of oncology drugs in 2012-2021 in China and the United States","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"R43-20260405","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ijc.33792","article-title":"Impact of the COVID-19 pandemic on population-based cancer registry","volume":"150","author":"Soerjomataram","year":"2022","journal-title":"Int J Cancer"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T04:00:27Z","timestamp":1775361627000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003969","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"2025-09-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}